Genomic Health Inc. (NASDAQ:GHDX) fell 1.4% during mid-day trading on Tuesday . The company traded as low as $26.76 and last traded at $27.10, with a volume of 269,364 shares traded. The stock had previously closed at $27.48.

A number of brokerages recently issued reports on GHDX. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Leerink Swann restated a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Jefferies Group raised their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, August 17th. Canaccord Genuity restated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 5th. Finally, Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a research report on Wednesday, August 3rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $32.44.

The company has a 50 day moving average of $28.02 and a 200 day moving average of $26.58. The firm’s market capitalization is $876.67 million.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.18). The business earned $81.97 million during the quarter, compared to the consensus estimate of $81.27 million. The company’s revenue was up 16.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) EPS. On average, equities analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current year.

In other news, Director Felix Baker acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was acquired at an average price of $27.02 per share, with a total value of $2,702,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $26.62, for a total transaction of $133,100.00. Following the sale, the chief operating officer now directly owns 40,226 shares of the company’s stock, valued at approximately $1,070,816.12. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Genomic Health stock. Schwab Charles Investment Management Inc. boosted its stake in Genomic Health Inc. (NASDAQ:GHDX) by 16.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,765 shares of the company’s stock after buying an additional 9,308 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.20% of Genomic Health worth $2,315,000 at the end of the most recent reporting period.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.